Evergreen Therapeutics Announces Agreement With ICON Plc To Conduct Phase II Clinical Trial For COVID-19 Drug Candidate
Evergreen Therapeutics, Inc. ("Evergreen," or the "Company"), a fast-growing clinical stage company focused on the development of new drugs for unmet medical needs, today announced a clinical service